Alector LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: $514.8M

Website

Clinical Trials

Continuation Study for Latozinemab

Phase 3

Conditions: Neurodegenerative Diseases

Interventions: Drug: Latozinemab

First Posted Date: 2023-11-01

Last Posted Date: 2024-01-05

Lead Sponsor: Alector Inc.

Target Recruit Count: 35

Registration Number: NCT06111014

Locations: 🇳🇱
Erasmus MC-Dr. Molewaterplein 40, Rotterdam, Netherlands
🇵🇹
Centro Hospitalar E Universitario de Coimbra EPE, Coimbra, Portugal
🇵🇹
Centro Hospitalar Universitário Lisboa Norte, EPE - Hospital de Santa Maria, Lisboa, Portugal

and more 20 locations

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

Phase 2

Recruiting

Conditions: Alzheimer's Disease

Interventions: Drug: AL002

First Posted Date: 2023-02-27

Last Posted Date: 2024-07-10

Lead Sponsor: Alector Inc.

Target Recruit Count: 210

Registration Number: NCT05744401

Locations: 🇺🇸
SFM Clinical Research, LLC, Boca Raton, Florida, United States
🇺🇸
Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

and more 51 locations

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Phase 2

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo
Drug: AL001

First Posted Date: 2021-09-22

Last Posted Date: 2023-06-18

Lead Sponsor: Alector Inc.

Target Recruit Count: 5

Registration Number: NCT05053035

Locations: 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

Phase 2

Active, not recruiting

Conditions: Alzheimer Disease

Interventions: Drug: AL002
Drug: Placebo

First Posted Date: 2020-10-19

Last Posted Date: 2024-08-27

Lead Sponsor: Alector Inc.

Target Recruit Count: 328

Registration Number: NCT04592874

Locations: 🇺🇸
Brain Matters Research - ERG, Delray Beach, Florida, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
South Florida Neurology Associates, Boca Raton, Florida, United States

and more 84 locations

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Phase 3

Active, not recruiting

Conditions: Frontotemporal Dementia

Interventions: Drug: AL001
Drug: Placebo
Drug: Open label - AL001

First Posted Date: 2020-05-05

Last Posted Date: 2024-10-21

Lead Sponsor: Alector Inc.

Target Recruit Count: 110

Registration Number: NCT04374136

Locations: 🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
🇸🇪
Karolinska Universitetssjukhuset Huddinge - PPDS, Huddinge, Sweden
🇺🇸
Dignity Health, Phoenix, Arizona, United States

and more 58 locations

A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: AL101
Other: Placebo

First Posted Date: 2019-10-01

Last Posted Date: 2022-08-10

Lead Sponsor: Alector Inc.

Target Recruit Count: 88

Registration Number: NCT04111666

Locations: 🇺🇸
Study site, Orlando, Florida, United States

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

Phase 2

Active, not recruiting

Conditions: Frontotemporal Dementia

Interventions: Drug: AL001

First Posted Date: 2019-06-17

Last Posted Date: 2023-07-19

Lead Sponsor: Alector Inc.

Target Recruit Count: 40

Registration Number: NCT03987295

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇳🇱
Erasmus University Medical Center, Rotterdam, Netherlands
🇬🇧
University College London, London, United Kingdom

and more 9 locations

First in Human Study for Safety and Tolerability of AL003.

Phase 1

Completed

Conditions: Healthy
Alzheimer Disease

Interventions: Other: Saline Solution
Biological: AL003

First Posted Date: 2019-01-30

Last Posted Date: 2021-09-17

Lead Sponsor: Alector Inc.

Target Recruit Count: 54

Registration Number: NCT03822208

Locations: 🇺🇸
Brain Matters Research, Delray Beach, Florida, United States
🇺🇸
Synexus AES, The Villages, Florida, United States
🇺🇸
PPD Clinical Research Unit, Orlando, Florida, United States

and more 3 locations

A Phase I Study for Safety and Tolerability of AL002.

Phase 1

Completed

Conditions: Alzheimer Disease
Healthy

Interventions: Biological: AL002
Other: Saline Solution

First Posted Date: 2018-08-17

Last Posted Date: 2020-12-09

Lead Sponsor: Alector Inc.

Target Recruit Count: 69

Registration Number: NCT03635047

Locations: 🇺🇸
Brain Matters Research, Delray Beach, Florida, United States
🇺🇸
Compass Research - The Villages, The Villages, Florida, United States
🇺🇸
Compass Research - Orlando, Orlando, Florida, United States

and more 3 locations

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

Phase 1

Completed

Conditions: Healthy
Frontotemporal Dementia

Interventions: Other: Placebo
Biological: AL001

First Posted Date: 2018-08-17

Last Posted Date: 2020-07-27

Lead Sponsor: Alector Inc.

Target Recruit Count: 64

Registration Number: NCT03636204

Locations: 🇺🇸
Study site, Orlando, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Canada

and more 5 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy